๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma

โœ Scribed by Choo, S.P.; Chowbay, B.; Ng, Q.S.; Thng, C.H.; Lim, Cindy; Hartono, S.; Koh, T.S.; Huynh, H.; Poon, D.; Ang, M.K.; Chang, S.; Toh, H.C.

Book ID
123066185
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
642 KB
Volume
49
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase 2 study of erlotinib in patients w
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma
โœ Melanie B. Thomas; Romil Chadha; Katrina Glover; Xuemei Wang; Jeffrey Morris; Th ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 162 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND. Growth factor overexpression, including epidermal growth factor receptor (EGFR) expression, is common in hepatocellular cancers. Erlotinib is a receptor tyrosine kinase inhibitor with specificity for EGFR. The primary objective of this study was to determine the proporti